OBALON THERAPEUTICS INC·4

May 2, 7:23 AM ET

Rasdal Andrew P 4

4 · OBALON THERAPEUTICS INC · Filed May 2, 2018

Insider Transaction Report

Form 4
Period: 2018-04-30
Rasdal Andrew P
DirectorPresident, CEO & Exec Chairman
Transactions
  • Award

    Common Stock

    [F1]
    2018-04-30$3.27/sh+2,987$9,767457,058 total
Footnotes (1)
  • [F1]These shares were acquired under the Obalon Therapeutics, Inc. 2016 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
Signature
/s/ Nooshin Hussainy as attorney-in-fact for Andrew Rasdal|2018-05-02

Documents

1 file
  • 4
    marketforms-41863.xmlPrimary

    PRIMARY DOCUMENT